Prevalence and characteristics of malaria co-infection among individuals with visceral leishmaniasis in Africa and Asia: a systematic review and meta-analysis

Polrat Wilairatana1, Wetpisit Chanmol2, Pongruj Rattaprasert3, Frederick Ramirez Masangkay4, Giovanni De Jesus Milanez5, Kwuntida Uthaisar Kotepui2 and Manas Kotepui2*

Abstract

Background: Malaria and visceral leishmaniasis (VL) co-infection can occur due to the overlapping geographical distributions of these diseases; however, only limited data of this co-infection have been reported and reviewed. This study aimed to explore the pooled prevalence and characteristics of this co-infection using a systematic review approach.

Methods: The PubMed, Web of Science and Scopus databases were searched for relevant studies. The quality of these studies was assessed in accordance with strengthening the reporting of observational studies in epidemiology (STROBE) guidelines. The numbers of individuals co-infected with Plasmodium and VL and the total numbers of individuals with VL were used to estimate the pooled prevalence using random-effects models. Differences in age, sex and the presence of anemia and malnutrition on admission were compared between co-infected individuals and individuals with VL using a random-effects model; the results are presented as odds ratios (ORs) and 95% confidence intervals (CIs). Heterogeneity among the included studies was assessed and quantified using Cochrane Q and I² statistics.

Results: Of the 3075 studies identified, 12 met the eligibility criteria and were included in this systematic review. The pooled prevalence of Plasmodium infection among the 6453 individuals with VL was 13%, with substantial heterogeneity of the data (95% CI 7–18%, I² 97.9%). Subgroup analysis demonstrated that the highest prevalence of co-infection occurred in African countries, whereas the lowest prevalence occurred in Asian countries. Patients aged < 5 years had higher odds of having co-infection than having VL (co-infection, n = 202; VL, n = 410) (OR 1.66, 95% CI 1.37–2.01, I² 0%; P < 0.0001), whereas patients aged 20–29 years had lower odds of having co-infection than having VL (co-infection, n = 170; VL, n = 699) (OR 0.75, 95% CI 0.60–0.93, I² 18%; P = 0.01). Male patients had equivalent odds of having co-infection and having VL (co-infection, n = 525; VL, n = 2232) (OR 0.92, 95% CI 0.82–1.03, I² 0%; P = 0.50). Patients with co-infection had lower odds of having anemia at admission than those with VL (co-infection, n = 902; VL, n = 2939) (OR 0.64, 95% CI 0.44–0.93, I² 0%; P = 0.02). No difference in malnutrition at admission was found in the meta-analysis.

*Correspondence: manas.ko@wu.ac.th
2 Medical Technology, School of Allied Health Sciences, Walailak University, Tha Sala, Nakhon Si Thammarat 80160, Thailand
Full list of author information is available at the end of the article

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: The prevalence of malaria co-infection among individuals with VL was heterogeneous and ranged from 7 to 18%, depending on geographical area. Age and anemia at admission were associated with co-infection status. Further longitudinal studies are needed to determine if co-infection with malaria has an impact on the severity of VL.

Keywords: Co-infection, Leishmania, Leishmaniasis, Malaria, Plasmodium, Visceral leishmaniasis

Background
Malaria is transmitted to humans via the bite of Anopheles mosquitoes harboring a protozoan parasite of the genus Plasmodium [1]. Seven species of the genus Plasmodium can infect humans, including Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale curtisi, Plasmodium ovale wallikeri, Plasmodium malariae, Plasmodium knowlesi and Plasmodium cynomolgi [2–4].

Malaria is a major public health concern worldwide, particularly in sub-Saharan Africa, a region that accounts for 93% of malaria cases and 94% of deaths due to the disease globally [1]. According to World Malaria Report 2019 [5], a total of 216 million malaria cases occurred worldwide in 2019 and resulted in nearly 445,000 deaths; of these deaths, 91% occurred in the World Health Organization (WHO) Africa region, 6% in the WHO South-east Asia Region, and 3% in the WHO eastern Mediterranean region [1]. In 2018, global malaria cases and deaths were estimated at 228 million and 405,000, respectively [5].

Leishmaniasis is a neglected infectious disease caused by protozoa of the genus Leishmania. Humans and animals can be infected with Leishmania spp. through the bites of Leishmania-infected sand flies [6]. Leishmaniasis can be classified into three clinical forms: cutaneous leishmaniasis, mucocutaneous leishmaniasis and visceral leishmaniasis (VL) [6]. In Africa and Asia, VL is mainly caused by Leishmania donovani, whereas in the Mediterranean region and in South America and Central America, VL is caused by Leishmania infantum [7]. A minority of VL cases are caused by Leishmania tropica [8]. According to the most recent publication on VL from the WHO [9], 50,000–90,000 new VL cases were reported annually during the time frame of the report. In addition, >90% of these new cases were reported in ten countries: Brazil, Ethiopia, Eritrea, India, Iraq, Kenya, Nepal, Somalia, Sudan and South Sudan [9].

Malaria and leishmaniasis have overlapping geographical distributions [10, 11]. Therefore, co-infection with Plasmodium spp. can occur in patients with VL, but this co-infection has only been reported in a limited number of studies and is considered rare [12–15]. Thus, this co-infection can lead to significant delays in the diagnosis of leishmaniasis [12] and severe disease if left undiagnosed. The aim of this systematic review and meta-analysis was to determine the prevalence and characteristics of malaria (caused by either P. falciparum or P. vivax) co-infection among individuals with VL (caused by L. donovani). Understanding the prevalence and characteristics of this co-infection may help physicians to recognize it among individuals with VL.

Methods
Protocol and registration
The protocol for the systematic review was registered with the Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD42020211018. The systematic review and meta-analysis followed preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [16].

Eligibility criteria
The inclusion criteria for the systemic review and meta-analysis were (i) the primary study had to report the number of patients co-infected with Plasmodium and VL, and (ii) the study had to identify the odds of co-infection compared to the number of individuals with VL or Plasmodium infection alone. Case reports or case series, conference abstracts and letters to editors were excluded. Only studies published after 1948 in the English language were considered eligible for inclusion.

Information sources and search strategy
The PubMed, Web of Science and Scopus databases were searched for potentially relevant studies. The search was performed using terms describing the two diseases (malaria and leishmaniasis) and terms reflecting the co-infection status (i.e., co-infection and concomitant infection) (Additional file 1: Table S1). The reference lists of eligible studies were also searched for additional articles that may have been missed in the initial search.

Study selection
Potentially relevant studies were independently screened by two authors (MK and WC) via a review of titles and abstracts. The full texts of potentially relevant studies were examined and selected according to the eligibility criteria. Disagreements on study selection were resolved through discussion.
Outcomes and data collection process
The major outcome of interest was the prevalence of Plasmodium and VL co-infection. The following information was extracted from the included studies: first author, publication year, year of the study, study design, study population, method used to identify Plasmodium and VL infections, number of co-infections, number of Plasmodium mono-infections and number of VL cases. The data from the included studies were extracted and transferred to a standardized pilot datasheet. Two authors (MK and WC) independently extracted the data. The data were cross-checked by another author (PW).

Quality of the included studies
The risk of bias in the included studies was assessed using the strengthening the reporting of observational studies in epidemiology (STROBE) guidelines [17]. The studies were categorized as high quality (meeting over 75% of the STROBE checklist criteria) and low quality (meeting under 75% of the STROBE checklist criteria) [18]. Low-quality studies were included in this review, but were analyzed separately or excluded from the sensitivity analysis [18].

Synthesis of results
All of the included studies were assessed by a qualitative (narrative) synthesis and a quantitative synthesis (meta-analysis). The numbers of patients with Plasmodium and VL co-infection and the total numbers of patients with VL in the individual studies were used to determine the pooled prevalence. The pooled prevalence of Plasmodium and VL co-infection was estimated from the studies that reported the number of co-infections and the total number of cases of VL using a random-effects model because the studies from which data were pooled were conducted in different settings and showed substantial heterogeneity. The prevalence of Plasmodium and VL co-infection in each study was also presented in a forest plot and was described separately in the narrative synthesis. Differences in age, sex and presence of anemia and malnutrition on admission between patients with co-infection and those with VL were compared using random-effects models and are presented as odds ratios (ORs) and 95% confidence intervals (CIs). Heterogeneity among the included studies was assessed and quantified using Cochrane Q and I² statistics. A Cochrane Q statistic with P<0.1 demonstrated significant heterogeneity across the included studies, whereas an I² value of >50% was considered to reflect substantial heterogeneity [19]. Subgroup analyses of country, year trend (publication years), and diagnostic test for VL were performed to evaluate the differences in the prevalence of Plasmodium and VL co-infection between studies. A subgroup analysis of age (<5 years, 5–9 years, 10–19 years, 20–29 years and ≥30 years) between patients with co-infection and those with VL was compared using a random-effects model. The sensitivity analysis of the pooled prevalence of co-infections was performed by excluding low-quality studies, and the pooled prevalence was estimated using both fixed- and random-effects models to achieve robustness of the review and conclusion.

Publication bias
Funnel plots were constructed to assess the publication bias among the included studies. An asymmetrical distribution in the funnel plot suggested that publication bias was likely, whereas a symmetrical distribution suggested that publication bias was unlikely. All statistical analyses were performed with Stata version 14.0 (StataCorp, College Station, TX) and Review Manager Version 5.3 (Cochrane Collaboration, London, UK).

Results
Search results
Of the 3075 studies identified by searching the three databases, 2922 were retained after removing those with duplicate data. After screening their titles and abstracts, 2868 of these studies were found not to meet the eligibility criteria and were removed. The full texts of the remaining 54 studies were examined, and 47 of these were excluded for the following reasons: 22 were review articles, nine did not report co-infections, five were studies carried out in vitro, four were case reports, three were mathematical modeling studies, one was a letter to the editor, one reported cutaneous leishmaniasis, one followed the same participants as another study and one contained unextractable data. Thus, a total of seven studies [20–26] remained and were included in the systematic review and meta-analysis. An additional three studies [27–29], identified through the review of reference lists of the included studies, and two studies [30, 31] identified from Google Scholar, were also included, resulting in a overall total of 12 studies [20–31] (Fig. 1).

Characteristics of the included studies
Most of the included studies had cross-sectional (50%, 6/12), cohort (33.3%, 4/12) or case–control designs (16.7%, 2/12) (Table 1). Most of the studies were conducted in Africa (84.6%, 10/12), and a minority were conducted in Asia (15.4%, 2/12). Of the studies conducted in Africa, most were conducted in either Ethiopia (33.3%, 4/12), Uganda (25%, 3/12), or Sudan (25%, 3/12). The studies from Asia were conducted in India [22] and Bangladesh [23]. The participants enrolled in the studies were
3 studies were retrieved from reviewing the reference lists of the included studies and 2 studies were retrieved from reviewing the Google Academic. 3076 studies were identified through database searching 2898 Scopus 97 PubMed 80 Web of Science 153 duplicates were removed. 2,922 studies were screened for title and abstract. 2,868 studies were excluded due to non-relevant studies. 47 of full-text articles were excluded, with reasons: 22 Review articles 9 No co-infection reported 5 In vitro research 4 Case reports 3 Mathematical models 1 Cutaneous leishmaniasis 1 Letter to the editor 1 Study using the same participants 1 Unable to extract the data. 54 full-text articles were assessed for eligibility. 7 studies met the eligibility criteria. 12 studies were included in qualitative and quantitative synthesis.

Fig. 1 Flow diagram showing the selection procedure for study inclusion in the systematic review and meta-analysis.

patients with suspected VL (50%, 6/12), patients with VL (41.7%, 5/12), and migrant laborers (8.3%, 1/12).

All the included studies identified Plasmodium infection using microscopy or a rapid diagnostic test (RDT). For the identification of VL infection, four of the included studies used immuno-chromatographic techniques (ICTs) or RDTs [20, 24, 27, 28]; three studies used ICTs, microscopic examination and direct agglutination tests (DATs) [25, 26, 29]; three studies used DATs and microscopy [21, 30, 31]; and one study used DATs and bone marrow aspiration (smear and culture) [22]. The presence of anemia and malnutrition at admission in patients with co-infection and those with VL was reported in three studies [25, 26, 30] (Additional file 2: Table S2).

**Quality of the included studies**

The risk of bias in the included studies was assessed using STROBE. Eleven of the studies [20, 21, 23–31] were of high quality, whereas the other one [22] was of low quality (Additional file 3: Table S3).

**Prevalence of Plasmodium infection among patients with VL**

The pooled prevalence of Plasmodium infection among patients with VL was estimated using a random-effects model in ten studies; two studies [26, 28] were excluded from the analysis because they were case–control ones. The pooled prevalence of Plasmodium infection among patients with VL was 13%, with substantial heterogeneity (95% CI 7–18%; $I^2$ 97.9%) (Fig. 2).

A subgroup analysis of countries was performed to assess the potential differences in the geographical distribution of co-infections. The highest prevalence of co-infection was reported in African countries, including Ethiopia (16%; 95% CI 2–30%, $I^2$ 97.5%; four studies), Uganda (20%; 95% CI 18–21%, $I^2$ 99.2%; two studies).
| Study no | First author and year of publication | Study area (years of survey) | Study design | Participants (n) | Age range (years) | Males (n, %) | Diagnostic methods | Plasmodium sp. and VL co-infection (n) | Plasmodium spp. mono-infection (n) | VL cases (n) |
|----------|-------------------------------------|----------------------------|--------------|-------------------|-------------------|--------------|-------------------|---------------------------------------|----------------------------------|-------------|
| 1        | Amare 2017 [30] Ethiopia (2010–2016) | Retrospective cohort study | VL and malaria co-infection (123), VL mono-infected patients (387) | Co-infection, mean 24.1 ± 7.9 years (0–9 years (n = 5), 10–19 years (n = 23), 20–29 years (n = 65), ≥30 years (n = 29); VL cases, mean 25.3 ± 7.8 years (0–9 years (n = 9), 10–19 years (n = 66), 20–29 years (n = 210), ≥30 years (n = 99)) | Co-infection, 121, 98.4%; VL, 361, 98.4% | Malaria detection, thick blood film examination, RDT; VL detection, serologic tests, DAT, bone marrow or lymph node aspiration (smear) | 123 NS 387 |
| 2        | Aschale et al. 2019 [20] Ethiopia (2016) | Cross-sectional study | Migrant labor 

| All participants, mean 26.1 ± 8.6 years (15–29 years (n = 132), 30–44 years (n = 38), 45–59 years (n = 4), ≥60 years (n = 4); co-infection [age 15–29 years (80%)]) | All participants 163, 91.6% | No report | 5 40 17 |
| 3        | de Beer et al. 1991 [27] Sudan (NS) | Prospective cohort study | Patients with various clinical disorders (2714), patients with suspected VL (1195) | NS | NS | Malaria detection, thin and thick blood film examination; VL detection, ICT using anti-Leishmania donovani antibody | 70 NS 584 |
| Study no | First author and year of publication | Study area (years of survey) | Study design | Participants (n) | Age range (years) | Males (n, %) | Diagnostic methods | Plasmodium sp. and VL co-infection (n) | Plasmodium spp. mono-infection (n) | VL cases (n) |
|----------|------------------------------------|-------------------------------|--------------|-----------------|-----------------|-------------|-------------------|--------------------------------------|---------------------------------|-------------|
| 4        | Ferede et al. 2017 [21]            | Ethiopia (2014)               | Cross-sectional study | Patients with suspected VL (384) | All participants, mean 28.1 ± 11.8 years (< 5 years (n = 6), 5–14 years (n = 20), 15–29 years (n = 227), 30–44 years (n = 99), ≥ 45 years (n = 32)); co-infection (< 5 years (n = 2), 5–14 years (n = 0), 15–29 years (n = 5), 30–44 years (n = 0), ≥ 45 years (n = 0)); individuals without malaria and VL co-infection (< 5 years (n = 4), 5–14 years (n = 20), 15–29 years (n = 218), 30–44 years (n = 94), ≥ 45 years (n = 32)) | 334, 87% Co-infection, 15, 93.8%; individuals without malaria and VL co-infection, 319, 95.5% | Malaria detection, thin and thick blood film examination; VL detection, DAT, microscopy | 16 | 45 (40 Plasmodium falciparum, five Plasmodium vivax) | 83 (Individuals without malaria and VL co-infection) |
| 5        | Kołaczinski et al. 2008 [28]       | Uganda (2006)                 | Case–control study | Patients with VL (93) | Confirmed VL, median 11 (IQR 8–16) years | 237, 75.7% Co-infection, 23, 79.3%; patients with VL (256), mean 31.5 ± 12.3 | Malaria detection, RDT; VL detection, ICT using anti-L. donovani antibody | 6 | NS | 87 |
| 6        | Mohammed et al. 2016 [31]          | Sudan (2013–2014)             | Retrospective cross-sectional study | Patients with VL (313) | All participants, mean 31.4 ± 11.9, co-infection, mean 27.3 ± 10.1; patients with VL (256), mean 31.5 ± 12.3 | 237, 75.7% Co-infection, 23, 79.3%; patients with VL (256), 192, 75% | Malaria detection, thick blood film examination; VL detection, serologic tests, DAT, bone marrow or lymph node aspiration (smear) | 29 | NS | 256 |
| Study no. | First author and year of publication | Study area (years of survey) | Study design | Participants (n) | Age range (years) | Males (n, %) | Diagnostic methods | Plasmodium spp and VL co-infection (n) | Plasmodium spp mono-infection (n) | VL cases (n) |
|-----------|-------------------------------------|-----------------------------|--------------|------------------|------------------|-------------|-------------------|--------------------------------------|----------------------------------|-------------|
| 7         | Mueller et al. 2009 [29]            | Uganda (2000–2005)          | Retrospective cross-sectional study | Patients with suspected VL (3483), patients with confirmed VL (1858) | Confirmed VL (< 5 years (n = 335), 6–15 years (n = 818), 16–45 years (n = 650) ≥ 45 years (n = 311)) | All participants 1283, 69% | Malaria detection, thin and thick blood film examination; VL detection, ICT using anti-L. donovani antibody, microscopic examination, DAT | 387 NS 1471 |                          |             |
| 8         | Nandy et al. 1995 [22]              | India (1995)                | Cross-sectional study | Patients with suspected VL (68) | Co-infection (6–35 years) | Co-infection, 2, 50% | Malaria detection, thin and thick blood film examination; VL detection, DAT and bone marrow aspiration (smear and culture) | 4 NS 64 |                          |             |
| 9         | Sarker et al. 2003 [23]             | Bangladesh (2002)           | Cross-sectional study | Patients with VL (81) | NS | All participants 59, 72.8% | No report | 1 NS 80 |                          |             |
| 10        | Tekalign et al. 2020 [24]           | Ethiopia (2013–2018)        | Descriptive retrospective cohort study | Patients with VL (434) | Confirmed VL (< 5 years (n = 34), 5–15 years (n = 63), ≥ 15 years (n = 91)) | All participants 151, 80% | Malaria detection, thin and thick blood film examination; VL detection, ICT using anti-L. donovani antibody | 12 NS 422 |                          |             |
| Study no | First author and year of publication | Study area (years of survey) | Study design | Participants (n) | Age range (years) | Males (n, %) | Diagnostic methods | Plasmodium spp and VL co-infection (n) | Plasmodium spp mono-infection (n) | VL cases (n) |
|----------|-------------------------------------|-----------------------------|--------------|------------------|------------------|------------|-------------------|-------------------------------------|---------------------------------|--------------|
| 11       | van den Bogaart et al. 2012 [25]    | Uganda (2000–2006)           | Descriptive retrospective cohort study | Patients with suspected VL (4428), patients with confirmed VL (2511) | Co-infection, median 10 (IQR 6–16) years [< 5 years (n = 82), 5–9 years (n = 133), 10–19 years (n = 145), 20–29 years (n = 53), ≥ 30 years (n = 32)]; patients with VL, median 12 (IQR 7–21) years [< 5 years (n = 234), 5–9 years (n = 451), 10–19 years (n = 687), 20–29 years (n = 354), ≥ 30 years (n = 219)] | Co-infection, 311, 69.1%; patients with VL, 1350, 68.7% | Malaria detection, thin and thick blood film examination; VL detection, ICT using anti-L. donovani antibody, microscopic examination, DAT | 450 NS 1964 |
| 12       | van den Bogaart et al. 2013 [26]    | Sudan (2005–2010)            | Retrospective case–control study | Patients with VL (1324) | Co-infection [< 5 years (n = 120), 5–9 years (n = 77), 10–19 years (n = 92), 20–29 years (n = 50), ≥ 30 years (n = 61)]; VL cases [< 5 years (n = 176), 5–9 years (n = 180), 10–19 years (n = 225), 20–29 years (n = 135), ≥ 30 years (n = 137)] | Co-infection, 212, 52.5%; patients with VL, 501, 57.6% | Malaria detection, thin and thick blood film examination; VL detection, ICT using anti-L. donovani antibody, microscopic examination, DAT | 404 NS 870 |

DAT Direct agglutination test; ICT immune-chromatographic technique, IQR interquartile range, NS not specified, PCR polymerase chain reaction, RDT rapid diagnostic test, VL visceral leishmaniasis
and Sudan (10%; 95% CI 8–12%, $I^2$ 99.2%; two studies). The lowest prevalence of co-infection was reported in Asian countries, including India (6%) and Bangladesh (1%).

A subgroup analysis of the time trend (publication years) of co-infections was performed to assess their potential differences. The highest prevalences of co-infection were reported in 2019 (23%) [20], 2017 (22%) [21, 30], 2009 (21%) [29] and 2012 (19%) [25] (Fig. 3). The lowest prevalences of co-infection were reported in 1991 (11%) [27], 2016 (9%) [31], 1995 (6%) [22], 2020 (3%) [24] and 2008 (1%) [23].

A subgroup analysis of diagnostic tests for VL showed that the highest prevalence of co-infection was reported in studies that used microscopy and serological tests (16%, 95% CI 12–20%, $I^2$ 92.5%; six studies), whereas the lowest prevalence of co-infection was reported in those that used ICT alone (5%, 95% CI 4–6%, $I^2$ 99.8%; two studies) (Fig. 4).

**Sensitivity analysis of the pooled prevalence of co-infections**

The sensitivity analysis of the pooled prevalence of co-infections was performed by excluding the low-quality study by Nandy et al. [22]. Using the fixed-effects model, the pooled prevalence of *Plasmodium* infection among patients with VL was 12% (95% CI 11–13%, $I^2$ 0%; nine studies) (Additional file 4: Figure S1). Using the random-effects model, the pooled prevalence of *Plasmodium* infection among patients with VL was 13% (95% CI 12–15%, $I^2$ 99%; six studies).
7–20%, $I^2$ 98.1%; nine studies) (Additional file 5: Figure S2).

**Prevalence of Plasmodium infection among patients with VL**

In Africa, the prevalence of *Plasmodium* infection in patients with VL was reported in Ethiopia, Uganda and Sudan. In Asia, the prevalence of *Plasmodium* infection in patients with VL was reported in India and Bangladesh (Fig. 5).

**Difference in age between patients with Plasmodium co-infection and patients with VL**

Studies conducted in African countries [20, 21, 24–26, 29, 30] showed that co-infection was reported in children aged 0–14 years and adults aged ≥ 30 years. For Asia, a study conducted in India [22] showed that...
the age of patients with co-infection was 5–35 years, whereas a study conducted in Bangladesh [23] did not specify the age of patients.

For the meta-analysis, the age of patients with co-infection and patients with VL was available from three studies [25, 26, 30]. Patients aged < 5 years had higher odds of having the co-infection than having VL (co-infection, \(n = 202\); VL, \(n = 410\); OR 1.66, 95% CI 1.37–2.01, \(I^2\) 0%; \(P < 0.0001\)). Patients aged 5–9 years had equivalent odds of having co-infection and having VL (co-infection, \(n = 210\); VL, \(n = 631\); OR 1.14, 95% CI 0.74–1.76, \(I^2\) 81%; \(P = 0.56\)). Patients aged 10–19 years had equivalent odds of having co-infection and having VL (co-infection, \(n = 260\); VL, \(n = 978\); OR 0.89, 95% CI 0.74–1.05, \(I^2\) 0%; \(P = 0.16\)). Patients aged 20–29 years had lower odds of having co-infection than having VL (co-infection, \(n = 170\); VL, \(n = 699\); OR 0.75, 95% CI 0.60–0.93, \(I^2\) 18%; \(P = 0.01\)). Patients aged ≥ 30 years had equivalent odds of having co-infection and having VL (co-infection, \(n = 122\); VL, \(n = 455\); OR 0.81, 95% CI 0.61–1.07, \(I^2\) 37%; \(P = 0.14\)) (Fig. 6).

Difference in sex between patients with *Plasmodium* co-infection and patients with VL

In African countries, a high proportion of male patients (100%, 79.3% and 69.1%) was reported by Ferede et al. [21], Mohammed et al. [31] and van den Bogaart et al. [25], respectively. A study by van den Bogaart et al. [26] reported an equal proportion of male and female patients. In Asia, a study by Nandy et al. [22] in India showed that 50% of patients with co-infection were males, whereas no data on the sex of patients with co-infection were reported in a study conducted in Bangladesh [23].

For the meta-analysis, information on the sex of patients with co-infection (\(n = 525\)) and patients with VL (\(n = 2232\)) was available from three studies [25, 26, 30].
Male patients had equivalent odds of having co-infection and having VL (OR 0.92, 95% CI 0.078–1.08, $I^2$ 0%; $P$=0.29) (Fig. 7).

Differences in the proportion of patients with anemia at admission
Information about the presence of anemia at admission in patients with co-infection ($n=902$) and in patients with VL ($n=2939$) was available from three studies conducted in Africa [25, 26, 30]. The proportion of patients with anemia and co-infection was 87%, 94.2% and 100% in a study by Amare [30], van den Bogaart et al. [25] and van den Bogaart et al. [26], respectively. In the meta-analysis, patients with co-infection had lower odds of anemia at admission than patients with VL (OR 0.64, 95% CI 0.44–0.93, $I^2$ 0%; $P$=0.02) (Fig. 8).

Differences in the proportion of patients with malnutrition at admission
Information on the presence of malnutrition at admission in patients with co-infection ($n=352$) and in patients with VL ($n=1517$) was available from three studies conducted in Africa [25, 26, 30]. Patients with co-infection had lower odds of anemia at admission than patients with VL in two studies [25, 30], whereas no significant difference was found in the proportion of patients with malnutrition between the two groups in another study [26]. Overall, no significant differences in the proportions of patients with malnutrition were observed between the two groups (OR 0.78, 95% CI 0.43–1.43, $I^2$ 90%; $P$=0.42) (Fig. 9).

Publication bias
The funnel plots of the prevalence of *Plasmodium* co-infection among patients with VL in ten of the included studies [20–25, 27, 29–31] are shown in Fig. 10. The funnel plots are symmetrical, indicating no substantial
### Fig. 6

Associations between age and odds of malaria and VL co-infection. For abbreviations, see Fig. 2.

| Study or Subgroup | Co-infection Events | Total VL cases | Odds Ratio IV, Random, 95% CI | VL cases Events | Total | Odds Ratio IV, Random, 95% CI |
|-------------------|---------------------|----------------|-----------------------------|----------------|-------|-----------------------------|
| **1.1.1 Age < 5 years** | | | | | | |
| van den Bogaart et al. [25] | 82 | 450 | 234 | 1964 | 8.3% | 1.65 [1.25, 2.17] |
| van den Bogaart et al. [26] | 120 | 404 | 176 | 870 | 8.4% | 1.67 [1.27, 2.18] |
| **Subtotal (95% CI)** | 854 | 2834 | 16.7% | 1.66 [1.37, 2.01] |
| Total events | 202 | 410 | | | | |
| Heterogeneity: $\tau^2 = 0.00; Ch^2 = 0.00, df = 1 (P = 0.95); I^2 = 0\%$ |
| Test for overall effect: $Z = 5.13 (P < 0.00001)$ |

| **1.1.2 Age 5-9 years** | | | | | | |
| van den Bogaart et al. [25] | 133 | 450 | 451 | 1964 | 8.8% | 1.41 [1.12, 1.77] |
| van den Bogaart et al. [26] | 77 | 404 | 180 | 870 | 8.1% | 0.90 [0.67, 1.22] |
| **Subtotal (95% CI)** | 854 | 2834 | 16.9% | 1.14 [0.74, 1.76] |
| Total events | 210 | 631 | | | | |
| Heterogeneity: $\tau^2 = 0.08; Ch^2 = 5.39, df = 1 (P = 0.02); I^2 = 81\%$ |
| Test for overall effect: $Z = 0.59 (P = 0.56)$ |

| **1.1.3 Age 10-19 years** | | | | | | |
| Amare M. [30] | 23 | 123 | 66 | 387 | 5.6% | 1.12 [0.66, 1.89] |
| van den Bogaart et al. [25] | 145 | 450 | 687 | 1964 | 8.9% | 0.88 [0.71, 1.10] |
| van den Bogaart et al. [26] | 92 | 404 | 225 | 870 | 8.3% | 0.85 [0.64, 1.12] |
| **Subtotal (95% CI)** | 977 | 3221 | 22.9% | 0.89 [0.76, 1.05] |
| Total events | 260 | 978 | | | | |
| Heterogeneity: $\tau^2 = 0.00; Ch^2 = 0.87, df = 2 (P = 0.65); I^2 = 0\%$ |
| Test for overall effect: $Z = 1.40 (P = 0.16)$ |

| **1.1.4 Age 20-29 years** | | | | | | |
| Amare M. [30] | 65 | 123 | 210 | 387 | 6.9% | 0.94 [0.63, 1.42] |
| van den Bogaart et al. [25] | 55 | 450 | 354 | 1964 | 8.0% | 0.63 [0.47, 0.86] |
| van den Bogaart et al. [26] | 50 | 404 | 135 | 870 | 7.5% | 0.77 [0.54, 1.09] |
| **Subtotal (95% CI)** | 977 | 3221 | 22.4% | 0.75 [0.60, 0.93] |
| Total events | 170 | 699 | | | | |
| Heterogeneity: $\tau^2 = 0.01; Ch^2 = 2.43, df = 2 (P = 0.30); I^2 = 18\%$ |
| Test for overall effect: $Z = 2.56 (P = 0.01)$ |

| **1.1.5 Age > 30 years** | | | | | | |
| Amare M. [30] | 29 | 123 | 99 | 387 | 6.1% | 0.90 [0.56, 1.44] |
| van den Bogaart et al. [25] | 32 | 450 | 219 | 1964 | 7.1% | 0.61 [0.41, 0.90] |
| van den Bogaart et al. [26] | 61 | 404 | 137 | 870 | 7.8% | 0.95 [0.69, 1.32] |
| **Subtotal (95% CI)** | 977 | 3221 | 21.0% | 0.81 [0.61, 1.07] |
| Total events | 122 | 455 | | | | |
| Heterogeneity: $\tau^2 = 0.02; Ch^2 = 3.18, df = 2 (P = 0.20); I^2 = 37\%$ |
| Test for overall effect: $Z = 1.48 (P = 0.14)$ |

**Total (95% CI)** | 4639 | 15331 | 100.0% | 0.98 [0.81, 1.18] |
| Total events | 964 | 3173 | | | | |
| Heterogeneity: $\tau^2 = 0.09; Ch^2 = 55.49, df = 12 (P < 0.00001); I^2 = 78\%$ |
| Test for overall effect: $Z = 0.19 (P = 0.85)$ |
| Test for subgroup differences: $Ch^2 = 37.32, df = 4 (P < 0.00001), I^2 = 69.3\%$ |

### Fig. 7

Associations between sex and odds of malaria and VL co-infection. For abbreviations, see Fig. 2.

| Study or Subgroup | Co-infection Events | Total VL cases | Odds Ratio IV, Random, 95% CI | VL cases Events | Total | Odds Ratio IV, Random, 95% CI |
|-------------------|---------------------|----------------|-----------------------------|----------------|-------|-----------------------------|
| Amare M. [30] | 121 | 123 | 381 | 387 | 1.0% | 0.95 [0.18, 4.78] |
| van den Bogaart et al. [25] | 311 | 450 | 1350 | 1964 | 52.8% | 1.02 [0.82, 1.27] |
| van den Bogaart et al. [26] | 212 | 404 | 501 | 870 | 46.2% | 0.81 [0.64, 1.03] |
| **Subtotal (95% CI)** | 977 | 3221 | 100.0% | 0.92 [0.78, 1.08] |
| Total events | 644 | 2232 | | | | |
| Heterogeneity: $\tau^2 = 0.00; Ch^2 = 1.84, df = 2 (P = 0.40); I^2 = 0\%$ |
| Test for overall effect: $Z = 1.05 (P = 0.29)$ |
publication bias. Egger's test was also performed to evaluate the symmetry of the funnel plots and showed no evidence of small-study effects ($P = 0.895$), which reflected the symmetry of the funnel plots and the absence of publication bias in the pooled prevalence from the included studies.

**Discussion**

Both malaria and leishmaniasis are endemic in Africa and in some countries in Asia, where they are major public health problems. A systematic review and meta-analysis were conducted to determine the prevalence and characteristics of malaria co-infection among patients with VL. A total of 12 studies [20–31] were included in both the qualitative review and quantitative meta-analysis. The pooled prevalence of malaria among patients with VL was relatively high (13%), especially in African countries, such as Sudan (10%), Uganda (20%) and Ethiopia (16%). The majority of VL cases occurred in six countries (India, Bangladesh, Sudan, South Sudan, Ethiopia and Brazil) [11], and half of the cases identified in Africa were thought to occur in Sudan [32].

The high prevalence of malaria among patients with VL suggests that these patients may have an increased susceptibility to malarial infection, resulting from leishmaniasis-induced attenuation of the immune system [21, 26]. Previous studies suggested that acute or chronic VL can cause CD4 lymphopenia and a low CD4:CD8 ratio in the blood, whereas CD4 levels were increased in the bone marrow [33]. Low CD4 levels in the blood may increase an individual's susceptibility to malaria [15]. Malaria causes symptoms, such as fever, in patients with leishmaniasis and may also exacerbate its clinical impact. Malaria co-infection was reported to be associated with the deterioration of the clinical condition of patients with leishmaniasis [26]. By contrast, studies in animal models suggested that co-infection by *Leishmania* and *Plasmodium* may not cause disease exacerbation compared with *Leishmania* mono-infection [34]. A recent study conducted using a mouse model demonstrated that *Plasmodium* and *Leishmania* co-infection could reduce the severity of leishmaniasis via decreased levels of interferon-γ, tumor necrosis factor-α, interleukin-6...
and interleukin-10; together, the decreased levels of these factors results in a delayed development of leishmanial lesions [35].

The meta-analysis of the pooled prevalence of Plasmodium and VL co-infection indicated substantial heterogeneity among the included studies. The substantial heterogeneity in the prevalence of co-infection might be due to differences in disease endemicity or the prevalence of these two diseases across countries. Heterogeneity may also be explained by the higher prevalence of Plasmodium and VL co-infection in three African countries compared with that in south Asian countries, such as Bangladesh [23] and India [22]. Furthermore, differences in study participants, study design and study period might partially account for the substantial heterogeneity observed among the included studies. Moreover, the heterogeneity of the prevalence of co-infection might be due to the different time frames when the included studies were conducted. For example, in four studies conducted in Ethiopia [20, 21, 24, 30], the estimated pooled prevalence of co-infection in Ethiopia was 16%. Although two of these studies [20, 30] were conducted in the same country within a similar time frame, the other two [21, 24] showed heterogeneity in the prevalence of co-infection. The subgroup analysis of the time trend (publication year) of co-infections was performed to assess their potential differences. This analysis showed that the prevalence of co-infections might not depend on time, as the highest prevalences were reported in 2019 (23%), 2017 (22%), 2009 (21%) and 2012, whereas the lowest ones were reported in 1991 (11%), 2016 (9%), 1995 (6%), 2020 (3%) and 2008 (1%). For example, there was a wide gap in the prevalence of co-infections between 2020 (3%), 2019 (23%), 2017 (22%) and 2016 (9%). Therefore, the time trend was not the source of heterogeneity in the pooled prevalence of co-infection. The subgroup analysis of diagnostic tests for VL was performed to test whether these may have been the cause of the heterogeneity in the pooled prevalence of VL. The results showed a difference in the pooled prevalence of malaria and VL co-infections between studies that used microscopy and serological tests for VL diagnosis (16%) and those that used ICT alone for VL diagnosis (5%). Substantial heterogeneity was noted among the prevalences of each subgroup. For example, in studies using ICT alone, the prevalence of co-infections was 11% in a study conducted in Sudan [27], whereas the prevalence of co-infections was 3% in a study conducted in Ethiopia [24]. Heterogeneity in prevalence was also demonstrated in the studies using microscopy and serological tests. Therefore, the diagnostic test for VL was not the source of heterogeneity in the pooled prevalence of co-infection.

Although a high prevalence of Plasmodium and VL co-infection was demonstrated in Africa, a low prevalence was demonstrated in Asia, e.g. 1% prevalence in Bangladesh, which could be explained by the regular and correct use of bed nets [36] or efficient vector control programs such as indoor insecticide spraying programs [37, 38]. These programs reduced the number of malaria and VL cases. Bangladesh initiated a national VL elimination program in 2008 by training health staff, introducing rapid diagnostic testing and oral treatment at no cost to patients, and integrating vector control management methods; these types of programs have reduced and continue to eliminate the VL burden in Bangladesh [39]. Bangladesh also received a global fund to support the Bangladesh National Malaria Control Program in 2006, which successfully reduced the number of malaria cases in the country [40].

In the meta-analysis, increased odds of Plasmodium and VL co-infection was observed in children aged <5 years, whereas decreased odds was observed in adults aged 20–29 years. Children under 5 years of age are vulnerable to malaria and death [41]. Fatal malarial infections among children in areas with numerous cases of malaria are caused by the absence of immunity against the disease during the first 5 years of life. The odds of co-infection was lower in older patients with VL. This was clearly demonstrated in a study by van den Bogaart et al. [25], who reported that age greater than 20 years was a protective factor against malaria co-infection in patients with VL. A high prevalence of co-infection in adults may be attributable to a significant number of these individuals undertaking daily outdoor activities, such as farmers and laborers [20, 21]. Daily outdoor activities during nighttime in regions with warm climates, such as northwest Ethiopia, can result in exposure to the vectors of these two pathogens [20, 21].

In the meta-analysis of sex, male patients had equivalent odds of having co-infection and VL. Equivalent odds of having co-infection were demonstrated in three studies included in the meta-analysis of sex [25, 26, 30]. However, a study conducted in Ethiopia by Ferede et al. [21] demonstrated that Plasmodium and VL co-infections were more frequently found in males (93.8%). A high prevalence of co-infection in males may be expected as males tend to have outdoor jobs, which makes them more prone to being bitten by infective mosquitoes and sand flies than females, who tend to spend more time at home [21].

The meta-analysis showed a lower proportion of anemia in individuals with Plasmodium and VL co-infection than in those with VL. However, this was shown only in a study conducted in Sudan by van den Bogaart et al. [26], which suggested that co-infection was a
protective factor against anemia. In contrast, another study conducted in Uganda by van den Bogaart et al. [25] demonstrated no association between co-infection and anemia. These discrepant observations on the association between anemia and co-infection may result from differences in the recording of information in the countries where co-infection was reported. Because parasite density was not reported in these two studies, the possibility of co-infection that might have accelerated the destruction of infected red blood cells could not be assessed. Although anemia at admission is a hallmark of malaria and leishmaniasis co-infection that can lead to the deterioration of patients with leishmaniasis, the proportions of patients with severe anemia (severe malaria) were similar to those of patients with co-infection and VL.

Malnutrition may also be associated with co-infection. However, the meta-analysis of two studies [25, 26] demonstrated no significant difference in malnutrition status between patients with co-infection and those with VL. Nevertheless, the results of one of these studies [25] and another study [30] suggest that co-infection might be a protective factor for malnutrition, as lower odds were found for patients with co-infection than with VL. A study by van den Bogaart et al. [25] suggested that co-infection was a protective factor for mild to moderate malnutrition. This finding was supported by an in vivo study [42]. Another study suggested that malnutrition, such as iron deficiency, was associated with the growth of Plasmodium parasites in vitro [43]. One of the included studies suggested that co-infection might not be associated with fatality rates among patients with non-severe VL [25]. Similar to malnutrition, Plasmodium and VL co-infections are often neglected and might not always be classed as notifiable; therefore, physicians in VL-endemic areas are often not aware of these co-infections or lack experience and knowledge in managing them, which may lead to unnecessary delays in the initiation of treatment.

The present study had several limitations. First, there was a limited number of studies that estimated VL prevalence in Africa, Asia and South America. Therefore, the prevalence of co-infection might have been under-studied or under-reported. Hence the pooled prevalence of co-infection reported here may have been limited as a result. Second, there was a lack of data on patients with VL, resulting in a potential bias in the selection of control groups, as other infections might also have been present in the patients with VL. Third, the pooled prevalence of co-infection was not estimated from all patients with suspected malaria but only from patients with confirmed or suspected VL. Thus, the pooled prevalence for patients with suspected co-infection in areas where these two diseases are endemic could not be extrapolated from the pooled prevalence reported here. Fourth, the species of Plasmodium was not identified in all the included studies; therefore, a subgroup analysis of the species of Plasmodium could not be performed. However, P. falciparum is the dominant species in the regions covered by most of the studies on Africa.

Conclusions

This systematic review and meta-analysis assessed the prevalence of Plasmodium and VL co-infection. The prevalence of malaria co-infection among individuals with VL was heterogeneous and ranged from 7 to 18%, depending on geographical area. Based on this review, malaria and VL co-infection seem to be under-studied or under-reported as only a limited number of studies reported the incidence or prevalence of VL in African and Asian countries. More studies are needed to investigate the prevalence of malarial infection among individuals with VL. In addition, the impact of malaria co-infection on the severity of VL should also be investigated to determine if it leads to worse disease outcomes.

Abbreviations

CS: 95% Confidence intervals; DATs: Direct agglutination tests; ICTs: Immunochromatographic techniques; ORs: Odds ratios; PRISMA: Preferred reporting items for systematic reviews and meta-analyses; RDT: Rapid diagnostic test; STROBE: Strengthening the reporting of observational studies in epidemiology; VL: Visceral leishmaniasis; WHO: World Health Organization.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13071-021-05045-1.

Acknowledgements

This research was partially supported by the New Strategic Research (P2P) Project, Walailak University, Thailand. The funders had a role in the collection, analysis and interpretation of the data.

Authors’ contributions

PW, WC and MK designed the design, selected the included studies, extracted the data, carried out the statistical analysis and drafted the manuscript. KUK participated in the selection of the included studies, data extraction and drafting of the manuscript. PR, FRM and GDJM participated in reviewing manuscript. All authors read and approved the final manuscript.
Funding
None.

Availability of data and materials
All data relating to the present study are included in this manuscript.

Declarations

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflicts of interest regarding the publication of this article.

Author details
1 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand. 2 Medical Technology, School of Allied Health Sciences, Walter University, Thala Sala, Nakharon Si Thammarat 80160, Thailand. 3 Department of Protozoology, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand. 4 Department of Medical Technology, Institute of Arts and Sciences, Far Eastern University-Manila, 10100 Manila, Philippines. 5 Department of Medical Technology, Faculty of Pharmacy, University of Santo Tomas, 10100 Manila, Philippines.

Received: 31 August 2021   Accepted: 29 September 2021
Published online: 23 October 2021

References
1. World Health Organization. Malaria. 2020. https://www.who.int/news-room/fact-sheets/detail/malaria. Accessed 25 Jan 2021.
2. Ta TH, Hisam S, Larza M, Jiram AI, Ismail N, Rubio JM. First case of a naturally acquired human infection with Plasmodium cynomolgi. Malar J. 2014;13:68.
3. Grignard L, Shah S, Chua TH, Drakeley CJ, Forance KM. Natural human infections with Plasmodium cynomolgi and other malaria species in an elimination setting in Sabah, Malaysia. J Infect Dis. 2019;220:1946–9.
4. Imwong M, Madmanee W, Suswanasiri K, Kunasol C, Peto TJ, Tripura R, et al. Asymptomatic natural human infections with the simian malaria parasites Plasmodium cynomolgi and Plasmodium knowlesi. J Infect Dis. 2019;219:695–702.
5. World Health Organization. World malaria report 2019. 2019. https://apps.who.int/iris/handle/10665/330011. Accessed 15 Jan 2021.
6. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392:951–70.
7. Ziljstra EE. Visceral leishmaniasis: a forgotten epidemic. Arch Dis Child. 2016;101:561–7.
8. Khanna S, Datta S, Mondal D, Saha P, Bandhopadhyay SK, Roy S, et al. RFLPs of ITS, ITS1 and hsp70 amplicons and sequencing of ITS1 of recent clinical isolates of Kala-azar from India and Bangladesh confirms the association of L. tropica with the disease. Acta Trop. 2012;124:229–34.
9. World Health Organization. Leishmaniasis. 2021. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis. Accessed 15 Aug 2021.
10. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis. 2004;4:327–36.
11. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7:e35671.
12. Ab Rahman AK, Abdullah FH. Visceral leishmaniasis (kala-azar) and malaria co-infection in an immigrant in the state of Terengganu, Malaysia: a case report. J Microbiol Immunol Infect. 2011;44:72–6.
13. Bin Mohanna MA. Leishmaniasis, malaria, and schistosomiasis concurrently in an 8-year-old boy. Saudi Med J. 2015;36:494–6.
14. Ghimire PG, Ghimire P, Adhikari J, Chapagain A. A case report of visceral leishmaniasis and malaria co-infection with pancytopenia and splenomegaly—a diagnostic challenge. BMC Infect Dis. 2019;19:3.
15. Saha K, Chattopadhyay D, Kulpai DD. Concomitant kala-azar, malaria, and progressive unstable indeterminate leprosy in an 8-year-old child. J Trop Pediatr. 1998;44:247–8.
16. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandebroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9.
18. Gbreyehounnes EA, Bhagavathula AS, Seid MA, Tegegn HG. Anti-malarial treatment outcomes in Ethiopia: a systematic review and meta-analysis. Malar J. 2017;16:269.
19. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). 2021. www.training.cochrane.org/handbook. Accessed 13 Aug 2020.
20. Aschale Y, Ayehu A, Worlku L, Tesfa H, Birhanie M, Lemema W. Malaria- visceral leishmaniasis co-infection and associated factors among migrant laborers in West Armachilho district, north west Ethiopia: community based cross-sectional study. BMC Infect Dis. 2019;19:7.
21. Ferede G, Diro E, Getse T, Getnet G, Takele G, Yamsu A, et al. Visceral leishmaniasis-malaria co-infection and their associated factors in patients attending Metema Hospital, northwest Ethiopia: suggestion for integrated vector management. Malar Res Treat. 2017;2017:6816913.
22. Nandy A, Addy M, Guha SK, Maji AK, Chaudhuri D, Chatterjee P. Co-existent kala-azar and malaria in India. Trans R Soc Trop Med Hyg. 1995;89:516.
23. Parker CB, Chowdhury KS, Siddiqui NJ, Jamal MF, Rahman S, Momen A, et al. Clinical profile of Kala-azar in adults: as seen in Mymensingh Medical College Hospital, Mymensingh, Bangladesh. Mymensingh Med J. 2003;12:41–4.
24. Tekalign S, Aderaa C, den Boer M, Miecha H, Zewde A, Mulugeta D, et al. Clinical features and treatment outcomes of visceral leishmaniasis patients admitted to three centers in Oromia, Ethiopia. J Infect Dev Ctries. 2020;14:425–57.
25. van den Bogaart E, Berkhourt MM, Adams ER, Mens PF, Sentongo E, Mbulamberi DB, et al. Prevalence, features and risk factors for malaria co-infections amongst visceral leishmaniasis patients from Amudat Hospital, Uganda. PLoS Negl Trop Dis. 2012;6:e1617.
26. Van Den Bogaart E, Berkhourt MM, Nou AB, Mens PF, Talba ABA, Adams ER, et al. Concomitant malaria among visceral leishmaniasis in-patients from Gedaref and Sennar states, Sudan: a retrospective case-control study. BMC Public Health. 2013;13:1.
27. de Beer P, El Harith A, Deng LL, Semiao-Santos SJ, Chantal B, van Grootetheest M. A killing disease epidemic among displaced Sudanese population identified as visceral leishmaniasis. Am J Trop Med Hyg. 1991;44:283–9.
28. Kolacinski JH, Rethering R, Worku DT, Ochung A, Kashimiro J, Kabateere N, et al. Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda. Int J Epidemiol. 2008;37:344–52.
29. Mueller Y, Mbulamberi DB, Odermatt P, Hoffmann A, Loutan L, Chappuis F. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop Med Int Health. 2009;14:910–7.
30. Amare M. Assessment of factors associated with mortality among visceral leishmaniasis and malaria co-infected patients in northwest Ethiopia, a retrospective study. 2017. http://repository.ifpri.org/handle/123456789/1232. Accessed 23 Aug 2021.
31. Mohammed HB, Ali AA, Idriss MI, Gasmelseid KM, Yousif MM, Ibrahem AA, Abdallah TM. Prevalence of hepatitis B, hepatitis C, HIV and malaria co-infection among patients infected with visceral leishmaniasis in Gedaref, eastern Sudan. Glob J Infect Dis Clin Res. 2016;12:021–4.
32. Burki T. East African countries struggle with visceral leishmaniasis. Lancet. 2009;374:371–2.
33. Rohitga A, Agarwal SK, Rose M, Chattopadhyay D, Saha K, Blood, bone marrow and splenic lymphocyte subset profiles in Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1996;90:431–4.
34. Marques CS, Rolao N, Centeno-Lima S, Lousada H, Maia C, Campino L, et al. Studies in a co-infection murine model of Plasmodium chabaudi chabaudi and Leishmania infantum: interferon-gamma and interleukin-4 mRNA expression. Mem Inst Oswaldo Cruz. 2005;100:889–92.
35. Pinna RA, Silva-Dos-Santos D, Perce-da-Silva DS, Oliveira-Ferreira J, Villa-Verde DM, De Luca PM, et al. Malaria-cutaneous leishmaniasis co-infection: influence on disease outcomes and immune response. Front Microbiol. 2016;7:982.
36. Mondal D, Alam MS, Karim Z, Haque R, Boelaert M, Kroege A. Present situation of vector-control management in Bangladesh: a wake up call. Health Policy. 2008;87:369–76.
37. Bern C, Chowdhury R. The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J Med Res. 2006;123:275–88.
38. Chowdhury R, Chowdhury V, Faria S, Islam S, Maheswary NP, Akhter S, et al. Indoor residual spraying for kala-azar vector control in Bangladesh: a continuing challenge. PLoS Negl Trop Dis. 2018;12:e0006846.
39. Ahmed BNNS, Rahman M, Selim S, Bashar A, Rashid M, Lira FY, Choudhury TA, Mondal D. Kala-azar (visceral leishmaniasis) elimination in Bangladesh: successes and challenges. Curr Trop Med Rep. 2014;1:163–9.
40. Haque U, Overgaard HJ, Clements AC, Norris DE, Islam N, Karim J, et al. Malaria burden and control in Bangladesh and prospects for elimination: an epidemiological and economic assessment. Lancet Glob Health. 2014;2:e98–105.
41. World Health Organization. Malaria in children under five. 2018. https://www.who.int/malaria/areas/high_risk_groups/children/en/. Accessed 1 Sep 2020.
42. Nyakeriga AM, Troye-Blomberg M, Dorfman JR, Alexander ND, Back R, Kortok M, et al. Iron deficiency and malaria among children living on the coast of Kenya. J Infect Dis. 2004;190:439–47.
43. Koka S, Foller M, Lamprecht G, Boini KM, Lang C, Huber SM, et al. Iron deficiency influences the course of malaria in Plasmodium berghei-infected mice. Biochem Biophys Res Commun. 2007;357:608–14.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.